MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
A single-arm, open-label, dose exploratory study to evaluate the safety, efficacy, and
pharmacokinetics of autologous humanized anti-MAGE-A4 T cell receptor-engineered T cell
(TCR-T) in advanced solid tumors.